Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Cancer Biomarker Complements Prostate Test

By LabMedica International staff writers
Posted on 29 Aug 2011
A DNA-based biomarker blood test could supplement the prostate-specific antigen (PSA) test currently offered to screen men for prostate cancer. More...


A highly specific circulating biomarker like the Glutathione S-transferase P (GSTP1) enzyme would complement the PSA test and could greatly improve the accuracy of prostate cancer detection before recommending patients for an invasive biopsy.

A cross-disciplinary collaborative effort was conducted under the auspices of the University of Cincinnati (UC; Cincinnati, OH, USA) to perform a meta-analysis on data related to DNA methylation in bodily fluids. More than 2,000 human biologic samples from 1,635 prostate cancer cases and 573 controls were analyzed for the current study, including whole blood, plasma, urine, ejaculates, and other secretions. The data was collected from 22 studies in US and Europe performed between 2000 and 2009.

Alterations of the DNA methylation process are commonly associated with cancerous tumor growth and changes can be detected in bodily fluids. GSTP1 DNA methylation is particularly associated with prostate cancer and can be detected in the bloodstream using high throughput standardized molecular biology techniques. The scientists determined that GSTP1 was a statistically significant biomarker for prostate cancer and could increase the specificity of prostate cancer diagnosis by up to 70% as compared to using the PSA test alone.

Tianying Wu, MD, PhD, a molecular epidemiologist at UC, said, "The PSA test is highly sensitive, but it cannot differentiate between prostate cancer and benign prostatic conditions such as benign prostatic hyperplasia, leading many men to have unnecessary biopsies. Measuring GSTPI in plasma or urine is an easy and noninvasive test. This biomarker will give physicians reassurance regards to whether to conduct biopsies in selected patients." The DNA methylation test in whole blood samples is less sensitive to prostate cancer stages than the same test done in plasma, serum, or urine. The study was published online on June 7, 2011, in the British Journal of Cancer.

Related Links:

University of Cincinnati


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.